Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v20-FR | Version v17-EN | |
---|---|---|
Language | French | English |
Date Updated | 2022-12-20 | 2022-12-20 |
Drug Identification Number | 02444038 | 02444038 |
Brand name | MIFEGYMISO | MIFEGYMISO |
Common or Proper name | Mifepristone/Misoprostol | Mifepristone/Misoprostol |
Company Name | LINEPHARMA INTERNATIONAL LIMITED | LINEPHARMA INTERNATIONAL LIMITED |
Ingredients | MISOPROSTOL MIFEPRISTONE | MISOPROSTOL MIFEPRISTONE |
Strength(s) | 200MCG 200MG | 200MCG 200MG |
Dosage form(s) | TABLET KIT | TABLET KIT |
Route of administration | ORAL BUCCAL ORAL BUCCAL | ORAL BUCCAL ORAL BUCCAL |
Packaging size | Combipack - 1 box with 1 tablet of mifepristone 200mg tablet + 1 box with 4 tablets of 200mcg misoprostol | Combipack - 1 box with 1 tablet of mifepristone 200mg tablet + 1 box with 4 tablets of 200mcg misoprostol |
ATC code | G03XB | G03XB |
ATC description | OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM | OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM |
Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
Anticipated start date | 2022-11-23 | 2022-11-23 |
Actual start date | 2022-11-23 | 2022-11-23 |
Estimated end date | 2022-12-20 | 2022-12-20 |
Actual end date | 2022-12-20 | 2022-12-20 |
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | Mifegymiso(R) is available at Linepharma International Inc. Wholesaler. | Mifegymiso(R) is available at Linepharma International Inc. Wholesaler. |
Health Canada comments |